Acoramidis · Attruby

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Transthyretin Amyloidosis with Cardiomyopathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (2)
JP
  • for the treatment of adults with ATTR-CM in Japan
Product first approved 2025sec.gov
EU
  • For the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Product first approved 2025EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Transthyretin Amyloidosis with Cardiomyopathy
NCT07116473 · Eidos Therapeutics, a BridgeBio company
2026-11 – 2037-12 · Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related, Amyloidogenic Transthyretin (ATTR) Amyloidosis, Heart Disease, Cardiomyopathies, Amyloidosis, Hereditary, Transthyretin-Related, Polyneuropathies, Amyloidosis
What this study did
Other / comorbidity
NCT06563895 · Eidos Therapeutics, a BridgeBio company
2025-05-12 – 2032-12 · Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
What this study did
NCT04988386 · Eidos Therapeutics, a BridgeBio company
2021-10-27 – 2028-05-15 · Amyloid Cardiomyopathy, Transthyretin-Related
What this study did
NCT04882735 · Eidos Therapeutics, a BridgeBio company
2021-09-08 – 2026-10 · Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
What this study did
Phase 2 (2)
Transthyretin Amyloidosis with Cardiomyopathy
NCT03458130 · Eidos Therapeutics, a BridgeBio company
2018-04-27 – 2018-10-05 · Familial ATTR-CM (ATTRm-CM, or FAC), Wild-type ATTR-CM (ATTRwt-CM)
What this study did
Other / comorbidity
NCT03536767 · Eidos Therapeutics, a BridgeBio company
2018-08-08 – 2025-09-15 · Amyloid Cardiomyopathy
What this study did
Phase 1 (2)
Other / comorbidity
NCT04769479 · Eidos Therapeutics, a BridgeBio company
2021-03-28 – 2021-09-03 · Amyloidosis
What this study did
NCT04958135 · Alexion Pharmaceuticals, Inc.
2021-05-30 – 2021-08-04 · Healthy
What this study did
Phase 4 (3)
Transthyretin Amyloidosis with Cardiomyopathy
NCT07695701 · Eidos Therapeutics, a BridgeBio company
2026-07-28 – 2030-11 · Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
What this study did
NCT07306949 · Alexion Pharmaceuticals, Inc.
2025-10-01 – 2028-03-31 · Transthyretin-type Cardiac Amyloidosis
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Transthyretin Amyloidosis with Cardiomyopathy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Acoramidis (Attruby): this drugApprovedSmall moleculeTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
Patisiran (ONPATTRO)
Approved(overall)
RNA / oligonucleotideTransthyretin (TTR)
Reliable signal(overall)
NCT03997383: Change From Baseline at Month 12 in Six-Minute Walk Test (6-MWT) (Baseline, Month 12): Placebo (DB)/Patisiran (OLE) -21.345 meters (95% CI -68.268 to 12.75) | Patisiran (DB+OLE) -8.15 meters (95% CI -54.651 to 29.51)
Vutrisiran (AMVUTTRA)ApprovedRNA / oligonucleotideTransthyretin (TTR)Reliable signal
NCT04153149: Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162
Inotersen (Tegsedi)
US approval withdrawn(overall)
RNA / oligonucleotideTransthyretin (TTR)
Reliable signal(overall)
No reviewed efficacy summary in this indication
CliramitugPhase 3Monoclonal antibodyTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
Coramitug
Phase 3(overall)
Monoclonal antibodyTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
Eplontersen (Wainua)Phase 3RNA / oligonucleotideTransthyretin (TTR)Partial signal
NCT04136171: CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. missed
Nexiguran ZiclumeranPhase 3Gene therapy / editingTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
NucresiranPhase 3RNA / oligonucleotideTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Attruby (Acoramidis) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Phase 4Transthyretin Amyloidosis with CardiomyopathyRecruiting
Est. primary completion 2027-09-17 · NCT07298044 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
Phase 4Transthyretin Amyloidosis with CardiomyopathyRecruiting
Est. primary completion 2028-03-31 · NCT07306949 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3Amyloid Cardiomyopathy, Transthyretin-RelatedActive not recruiting
Est. primary completion 2028-04-15 · NCT04988386 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Phase 4Transthyretin Amyloidosis with CardiomyopathyRecruiting
Est. primary completion 2030-08 · NCT07695701 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 3Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, PolyneuropathiesRecruiting
Est. primary completion 2031-10 · NCT06563895 · CT.gov ↗
What to watch
2037 (1)
November 2037 (1)
Phase 3Transthyretin Amyloidosis with CardiomyopathyNot yet recruiting
Est. primary completion 2037-11 · NCT07116473 · CT.gov ↗
What to watch

See the full readout calendar ↗